[Recent Advances in Immunotherapy for Acute Myeloid Leukemia --Review].

Currently, the traditional chemotherapeutic drugs for acute myeloid leukemia (AML) showed significant curative efficacy, including the improving long-term prognosis and the life quality of the patients, however the traditional chemotherapeuatic drugs showed the some limitatious in the aspects of enhancing the complete remission rate of newly diagnosed AML patients, overcoming the relapse after remission,as well as the primary and secondary drug-resstance to chemotherapeutics. In order to improve the long-term prognisis of patients, the immuno therapy will the best choice for these patients. This review sammarizes the main current advance of immunotherapy of AML at home and abroad, such as antibody-drug conjugate(ADC), bispecific T cell engager (BiTE), chimeric type of antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors; dendritic cell vaccination and peptide vaccines; natural killer cell (NK) therapy and so on.急性髓系白血病免疫治疗最新研究进展.目前通过运用传统化疗药物治疗急性髓系白血病（acute myeloid leukemia，AML）已经取得了显著疗效，改善了患者的远期预后，提高了患者的生存质量，但在提高初治AML患者的完全缓解率、克服缓解后复发及对化疗药物原发及继发耐药等方面仍存在一定的局限性。为了改善患者的远期预后，免疫治疗将成为这部分患者的最佳选择。本文总结了目前国内外AML免疫治疗主要方法：抗体药物偶联(antibody-drug conjugate，ADC)；双特异性T细胞单链抗体（bispecific T cell engager， BiTE）；嵌合型抗原受体T细胞(CAR-T)疗法；免疫检查点抑制剂（checkpoint inhibitors）；树突状细胞疫苗和多肽疫苗（fendritic cell vaccination and peptide vaccines）；自然杀伤细胞（natural killer cell，NK）治疗等，重点探讨针对初治AML及复发难治性AML的免疫治疗。.